Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Nutrients ; 13(4)2021 Apr 13.
Article in English | MEDLINE | ID: mdl-33924402

ABSTRACT

BACKGROUND: Receptors located on enteroendocrine cells (EECs) of the colon can detect nutrients in the lumen. These receptors regulate appetite through a variety of mechanisms, including hormonal and neuronal signals. We assessed the effect of obesity on the expression of these G-protein coupled receptors (GPCRs) and hormones at both mRNA and protein level. METHODS: qPCR and immunohistochemistry were used to examine colonic tissue from cohorts of patients from the Netherlands (proximal and sigmoid tissue) and the United Kingdom (tissue from across the colon) and patients were grouped by body mass index (BMI) value (BMI < 25 and BMI ≥ 25). RESULTS: The mRNA expression of the hormones/signaling molecules serotonin, glucagon, peptide YY (PYY), CCK and somatostatin were not significantly different between BMI groups. GPR40 mRNA expression was significantly increased in sigmoid colon samples in the BMI ≥ 25 group, but not proximal colon. GPR41, GPR109a, GPR43, GPR120, GPRC6A, and CaSR mRNA expression were unaltered between low and high BMI. At the protein level, serotonin and PYY containing cell numbers were similar in high and low BMI groups. Enterochromaffin cells (EC) showed high degree of co-expression with amino acid sensing receptor, CaSR while co-expression with PYY containing L-cells was limited, regardless of BMI. CONCLUSIONS: While expression of medium/long chain fatty acid receptor GPR40 was increased in the sigmoid colon of the high BMI group, expression of other nutrient sensing GPCRs, and expression profiles of EECs involved in peripheral mechanisms of appetite regulation were unchanged. Collectively, these data suggest that in human colonic tissue, EEC and nutrient-sensing receptor expression profiles are not affected despite changes to BMI.


Subject(s)
Colon/metabolism , Intestinal Mucosa/metabolism , Obesity/metabolism , Receptors, G-Protein-Coupled/metabolism , Satiation/physiology , Adult , Aged , Aged, 80 and over , Animals , Biopsy , Body Mass Index , Case-Control Studies , Colon/cytology , Enteroendocrine Cells/metabolism , Female , Gene Expression Profiling , Healthy Volunteers , Humans , Intestinal Mucosa/cytology , Male , Middle Aged , Netherlands , Nutrients/metabolism , Obesity/diagnosis , Obesity/physiopathology , Receptors, G-Protein-Coupled/genetics , United Kingdom , Weight Gain/physiology
2.
Gut Microbes ; 11(6): 1745-1757, 2020 11 01.
Article in English | MEDLINE | ID: mdl-32515657

ABSTRACT

BACKGROUND AND AIMS: As the importance of gut-brain interactions increases, understanding how specific gut microbes interact with the enteric nervous system (ENS), which is the first point of neuronal exposure becomes critical. Our aim was to understand how the dominant human gut bacterium Bacteroides thetaiotaomicron (Bt) regulates anatomical and functional characteristics of the ENS. METHODS: Neuronal cell populations, as well as enteroendocrine cells, were assessed in proximal colonic sections using fluorescent immunohistochemistry in specific pathogen-free (SPF), germ-free (GF) and Bt conventionalized-germ-free mice (Bt-CONV). RNA expression of tight junction proteins and toll-like receptors (TLR) were measured using qPCR. Colonic motility was analyzed using in vitro colonic manometry. RESULTS: Decreased neuronal and vagal afferent innervation observed in GF mice was normalized by Bt-CONV with increased neuronal staining in mucosa and myenteric plexus. Bt-CONV also restored expression of nitric oxide synthase expressing inhibitory neurons and of choline acetyltransferase and substance P expressing excitatory motor neurons comparable to those of SPF mice. Neurite outgrowth and glial cells were upregulated by Bt-CONV. RNA expression of tight junction protein claudin 3 was downregulated while TLR2 was upregulated by Bt-CONV. The enteroendocrine cell subtypes L-cells and enterochromaffin cells were reduced in GF mice, with Bt-CONV restoring L-cell numbers. Motility as measured by colonic migrating motor complexes (CMMCs) increased in GF and Bt-CONV. CONCLUSION: Bt, common gut bacteria, is critical in regulating enteric neuronal and enteroendocrine cell populations, and neurogenic colonic activity. This highlights the potential use of this resident gut bacteria for maintaining healthy gut function.


Subject(s)
Bacteroides thetaiotaomicron/physiology , Colon/innervation , Colon/microbiology , Enteric Nervous System/physiology , Gastrointestinal Microbiome , Animals , Claudin-3/genetics , Claudin-3/metabolism , Colon/metabolism , Mice , Mice, Inbred C57BL , Neurons/metabolism , Nitric Oxide Synthase/genetics , Nitric Oxide Synthase/metabolism , Specific Pathogen-Free Organisms , Tight Junctions/genetics , Tight Junctions/metabolism , Toll-Like Receptor 2/genetics , Toll-Like Receptor 2/metabolism
3.
Sci Transl Med ; 11(486)2019 04 03.
Article in English | MEDLINE | ID: mdl-30944164

ABSTRACT

Long-term cotrimoxazole prophylaxis reduces mortality and morbidity in HIV infection, but the mechanisms underlying these clinical benefits are unclear. Here, we investigate the impact of cotrimoxazole on systemic inflammation, an independent driver of HIV mortality. In HIV-positive Ugandan and Zimbabwean children receiving antiretroviral therapy, we show that plasma inflammatory markers were lower after randomization to continue (n = 144) versus stop (n = 149) cotrimoxazole. This was not explained by clinical illness, HIV progression, or nutritional status. Because subclinical enteropathogen carriage and enteropathy can drive systemic inflammation, we explored cotrimoxazole effects on the gut microbiome and intestinal inflammatory biomarkers. Although global microbiome composition was unchanged, viridans group Streptococci and streptococcal mevalonate pathway enzymes were lower among children continuing (n = 36) versus stopping (n = 36) cotrimoxazole. These changes were associated with lower fecal myeloperoxidase. To isolate direct effects of cotrimoxazole on immune activation from antibiotic effects, we established in vitro models of systemic and intestinal inflammation. In vitro cotrimoxazole had modest but consistent inhibitory effects on proinflammatory cytokine production by blood leukocytes from HIV-positive (n = 16) and HIV-negative (n = 8) UK adults and reduced IL-8 production by gut epithelial cell lines. Collectively we demonstrate that cotrimoxazole reduces systemic and intestinal inflammation both indirectly via antibiotic effects on the microbiome and directly by blunting immune and epithelial cell activation. Synergy between these pathways may explain the clinical benefits of cotrimoxazole despite high antimicrobial resistance, providing further rationale for extending coverage among people living with HIV in sub-Saharan Africa.


Subject(s)
Gastrointestinal Microbiome , HIV Infections/drug therapy , HIV Infections/microbiology , Inflammation/drug therapy , Inflammation/immunology , Trimethoprim, Sulfamethoxazole Drug Combination/therapeutic use , CD4-Positive T-Lymphocytes/immunology , Child , Child, Preschool , Cytokines/metabolism , Disease Progression , Epithelial Cells/drug effects , Epithelial Cells/metabolism , Gastrointestinal Microbiome/drug effects , HIV Infections/immunology , Humans , Inflammation Mediators/metabolism , Intestines/drug effects , Intestines/pathology , Nutritional Status/drug effects , Phenotype , Streptococcus/drug effects , Trimethoprim, Sulfamethoxazole Drug Combination/pharmacology
4.
Sci Transl Med ; 9(402)2017 08 09.
Article in English | MEDLINE | ID: mdl-28794283

ABSTRACT

Immunotherapy using short immunogenic peptides of disease-related autoantigens restores immune tolerance in preclinical disease models. We studied safety and mechanistic effects of injecting human leukocyte antigen-DR4(DRB1*0401)-restricted immunodominant proinsulin peptide intradermally every 2 or 4 weeks for 6 months in newly diagnosed type 1 diabetes patients. Treatment was well tolerated with no systemic or local hypersensitivity. Placebo subjects showed a significant decline in stimulated C-peptide (measuring insulin reserve) at 3, 6, 9, and 12 months versus baseline, whereas no significant change was seen in the 4-weekly peptide group at these time points or the 2-weekly group at 3, 6, and 9 months. The placebo group's daily insulin use increased by 50% over 12 months but remained unchanged in the intervention groups. C-peptide retention in treated subjects was associated with proinsulin-stimulated interleukin-10 production, increased FoxP3 expression by regulatory T cells, low baseline levels of activated ß cell-specific CD8 T cells, and favorable ß cell stress markers (proinsulin/C-peptide ratio). Thus, proinsulin peptide immunotherapy is safe, does not accelerate decline in ß cell function, and is associated with antigen-specific and nonspecific immune modulation.


Subject(s)
Diabetes Mellitus, Type 1/therapy , Immunotherapy/methods , Peptides/therapeutic use , Proinsulin/therapeutic use , Adolescent , Adult , Autoantibodies/immunology , Autoantigens/immunology , C-Peptide/metabolism , Diabetes Mellitus, Type 1/metabolism , Double-Blind Method , Female , Humans , Immunophenotyping , Male , Middle Aged , T-Lymphocytes, Regulatory/metabolism , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...